Baudax Bio, Inc.
BXRXQ
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -22.50% | -15.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -22.50% | -15.30% |
| Cost of Revenue | -- | -- | -- | 731.94% | -- |
| Gross Profit | -- | -- | -- | -2,446.59% | -- |
| SG&A Expenses | 23.23% | -22.22% | -74.46% | -81.87% | -73.33% |
| Depreciation & Amortization | -- | -- | -- | -89.91% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.97% | 6.78% | -38.54% | -39.78% | -72.15% |
| Operating Income | -54.97% | -6.78% | 38.54% | 40.32% | 71.53% |
| Income Before Tax | 53.73% | -68.03% | 9.86% | -131.43% | 75.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 53.73% | -68.03% | 9.86% | -131.43% | 75.90% |
| Earnings from Discontinued Operations | 99.83% | 97.68% | 507.15% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.38% | 2.07% | 189.03% | -131.43% | -72.19% |
| EBIT | -54.97% | -6.78% | 38.54% | 40.32% | 71.53% |
| EBITDA | -51.68% | -7.18% | 38.47% | 40.42% | 71.50% |
| EPS Basic | 99.70% | 96.40% | 103.88% | -102.54% | 64.92% |
| Normalized Basic EPS | 98.13% | 93.94% | 96.07% | 94.82% | 93.66% |
| EPS Diluted | 99.70% | 96.40% | 103.88% | -102.82% | 64.92% |
| Normalized Diluted EPS | 98.13% | 93.94% | 96.07% | 94.23% | 93.66% |
| Average Basic Shares Outstanding | 2,601.42% | 2,621.56% | 2,195.54% | 1,139.83% | 390.71% |
| Average Diluted Shares Outstanding | 2,601.42% | 2,621.56% | 2,195.54% | 1,014.56% | 390.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |